Literature DB >> 21496982

Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients.

Joachim H Ix, Prerna Ganjoo, Diane Tipping, Andrew M Tershakovec, Andrew G Bostom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21496982     DOI： 10.1053/j.ajkd.2011.03.010

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  13 in total

Review 1.  The effect of chronic kidney disease on lipid metabolism.

Authors:  Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-12-05       Impact factor: 2.370

Review 2.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2014-04-01       Impact factor: 28.314

3.  Effect of niacin on FGF23 concentration in chronic kidney disease.

Authors:  Madhumathi Rao; Michael Steffes; Andrew Bostom; Joachim H Ix
Journal:  Am J Nephrol       Date:  2014-05-20       Impact factor: 3.754

Review 4.  Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-05       Impact factor: 2.894

5.  The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD.

Authors:  Rakesh Malhotra; Ronit Katz; Andrew Hoofnagle; Andrew Bostom; Dena E Rifkin; Ruth Mcbride; Jeffrey Probstfield; Geoffrey Block; Joachim H Ix
Journal:  Clin J Am Soc Nephrol       Date:  2017-12-05       Impact factor: 8.237

6.  Effects of phosphate binders in moderate CKD.

Authors:  Geoffrey A Block; David C Wheeler; Martha S Persky; Bryan Kestenbaum; Markus Ketteler; David M Spiegel; Matthew A Allison; John Asplin; Gerard Smits; Andrew N Hoofnagle; Laura Kooienga; Ravi Thadhani; Michael Mannstadt; Myles Wolf; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2012-07-19       Impact factor: 10.121

Review 7.  Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.

Authors:  Tamara Isakova; Joachim H Ix; Stuart M Sprague; Kalani L Raphael; Linda Fried; Jennifer J Gassman; Dominic Raj; Alfred K Cheung; John W Kusek; Michael F Flessner; Myles Wolf; Geoffrey A Block
Journal:  J Am Soc Nephrol       Date:  2015-05-12       Impact factor: 10.121

Review 8.  Phosphate control in end-stage renal disease: barriers and opportunities.

Authors:  Ahmed A Waheed; Fernando Pedraza; Oliver Lenz; Tamara Isakova
Journal:  Nephrol Dial Transplant       Date:  2013-07-30       Impact factor: 5.992

9.  Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.

Authors:  Joachim H Ix; Tamara Isakova; Brett Larive; Kalani L Raphael; Dominic S Raj; Alfred K Cheung; Stuart M Sprague; Linda F Fried; Jennifer J Gassman; John P Middleton; Michael F Flessner; Geoffrey A Block; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2019-05-13       Impact factor: 10.121

Review 10.  Phosphate and FGF-23 homeostasis after kidney transplantation.

Authors:  Leandro C Baia; Ita Pfeferman Heilberg; Gerjan Navis; Martin H de Borst
Journal:  Nat Rev Nephrol       Date:  2015-09-29       Impact factor: 28.314
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.